Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Grants and contracts	$ 997,839	$ 0
Cost of goods sold	353,671	0
Gross Profit	644,168	0
Operating expenses:
Research and development	3,242,328	1,024,344
Sales and marketing expense	37,036	2,796
General and administrative	3,978,349	4,166,889
Total operating expenses	7,257,713	5,194,029
Loss from operations	(6,613,545)	(5,194,029)
Other expense:
Interest and other expense	(1,146,388)	(92,617)
Total other expense	(1,146,388)	(92,617)
Income from discontinued operations, net of income taxes	0	0
Net loss	(7,759,933)	(5,286,646)
Net loss attributable to noncontrolling interests	2,723	0
Net loss attributable to Statera Biopharma, Inc.	$ (7,757,210)	$ (5,286,646)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.20)	$ (0.22)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	38,255,406	24,423,700